Cytostatic Action of Novel Histone Deacetylase Inhibitors in Androgen Receptor-Null Prostate Cancer Cells

Androgen receptor (AR)-null prostate tumors have been observed in 11-24% of patients. Histone deacetylases (HDACs) are overexpressed in prostate tumors. Therefore, HDAC inhibitors (Jazz90 and Jazz167) were examined in AR-null prostate cancer cell lines (PC3 and DU145). Both Jazz90 and Jazz167 inhibited the growth of PC3 and DU145 cells. Jazz90 and Jazz167 were more active in PC3 cells and DU145 cells in comparison to normal prostate cells (PNT1A) and showed a 2.45- and 1.30-fold selectivity and higher cytotoxicity toward DU145 cells, respectively. Jazz90 and Jazz167 reduced HDAC activity by similar to 60% at 50 nM in PC3 lysates. At 4 mu M, Jazz90 and Jazz167 increased acetylation in PC3 cells by 6- to 8-fold. Flow cytometry studies on the cell phase distribution demonstrated that Jazz90 causes a G(0)/G(1) arrest in AR-null cells, whereas Jazz167 leads to a G(0)/G(1) arrest in DU145 cells. However, apoptosis only occurred at a maximum of 7% of the total cell population following compound treatments in PC3 and DU145 cells. There was a reduction in cyclin D1 and no significant changes in bcl-2 in DU145 and PC3 cells. Overall, the results showed that Jazz90 and Jazz167 function as cytostatic HDAC inhibitors in AR-null prostate cancer cells.

Automated summary

Jazz90 and Jazz167 act as cytostatic HDAC inhibitors in AR-null prostate cancer cells by inhibiting cell growth with selective cytotoxicity, reducing HDAC activity, and increasing acetylation levels in cells. However, their apoptotic effects on PC3 and DU145 cells are limited, showing only a maximum of 7% cell population undergoing apoptosis after treatment with the compounds.